CC Small or few human trials. Promising, not proven. How we grade →Animal study · Mice treated for 3 months from 20 months of age
Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice
A Bitto, T Ito, V Pineda, N LeTexier, H Huang, E Sutlief et al. eLife. 2016.
- In plain language
- Three months of rapamycin in middle-aged male mice raised median remaining life by 60% from the end of treatment (16% from birth); at one dose, females did not live longer and had more aggressive blood cancers.
- Limits
- Mouse data, single lab, injected drug.
- Which of our grades it feeds
- DD Mostly mechanistic or early data. Shown openly. How we grade →Science summary: Rapamycin and mTOR: strong mouse lifespan data, early human trials
- Source
- doi.org/10.7554/eLife.16351 · PubMed 27549339 · Free full text
Summary written by Everstack from the published abstract. Verified against Crossref on 2026-10-15. The authors do not endorse Everstack. We sell some of what we grade.